AU2013323360B2 - Azaquinazoline inhibitors of atypical protein kinase C - Google Patents
Azaquinazoline inhibitors of atypical protein kinase C Download PDFInfo
- Publication number
- AU2013323360B2 AU2013323360B2 AU2013323360A AU2013323360A AU2013323360B2 AU 2013323360 B2 AU2013323360 B2 AU 2013323360B2 AU 2013323360 A AU2013323360 A AU 2013323360A AU 2013323360 A AU2013323360 A AU 2013323360A AU 2013323360 B2 AU2013323360 B2 AU 2013323360B2
- Authority
- AU
- Australia
- Prior art keywords
- pyridin
- pyrido
- pyrimidin
- piperazin
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707340P | 2012-09-28 | 2012-09-28 | |
| US61/707,340 | 2012-09-28 | ||
| US201361781364P | 2013-03-14 | 2013-03-14 | |
| US61/781,364 | 2013-03-14 | ||
| PCT/US2013/062085 WO2014052699A1 (en) | 2012-09-28 | 2013-09-27 | Azaquinazoline inhibitors of atypical protein kinase c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013323360A1 AU2013323360A1 (en) | 2015-04-30 |
| AU2013323360B2 true AU2013323360B2 (en) | 2017-09-07 |
Family
ID=49326872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013323360A Active AU2013323360B2 (en) | 2012-09-28 | 2013-09-27 | Azaquinazoline inhibitors of atypical protein kinase C |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9914730B2 (enExample) |
| EP (1) | EP2900666B1 (enExample) |
| JP (1) | JP6535430B2 (enExample) |
| KR (1) | KR102215272B1 (enExample) |
| CN (1) | CN105102456B (enExample) |
| AU (1) | AU2013323360B2 (enExample) |
| BR (1) | BR112015007061B1 (enExample) |
| CA (1) | CA2886495C (enExample) |
| CL (1) | CL2015000781A1 (enExample) |
| EA (1) | EA030253B1 (enExample) |
| IL (1) | IL237918B (enExample) |
| MX (1) | MX372736B (enExample) |
| NZ (1) | NZ706857A (enExample) |
| PH (1) | PH12015500689A1 (enExample) |
| SG (1) | SG11201502301YA (enExample) |
| TW (1) | TWI663165B (enExample) |
| WO (1) | WO2014052699A1 (enExample) |
| ZA (1) | ZA201502783B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX372736B (es) * | 2012-09-28 | 2020-06-19 | Cancer Research Tech Ltd | Inhibidores de azaquinazolina de la proteina quinasa c atipica. |
| JP6391120B2 (ja) | 2012-12-20 | 2018-09-19 | サンフォード−バーンハム メディカル リサーチ インスティテュート | ニューロテンシン受容体１の小分子アゴニスト |
| GEP201706780B (en) | 2013-03-14 | 2017-11-27 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| NZ718190A (en) | 2013-08-23 | 2017-10-27 | Neupharma Inc | Substituted quinazolines for inhibiting kinase activity |
| WO2015143376A1 (en) * | 2014-03-21 | 2015-09-24 | Nivalis Therapeutics, Inc. | Novel compounds for the treatment of cystic fibrosis |
| TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑 |
| WO2015200534A2 (en) | 2014-06-25 | 2015-12-30 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2016037106A1 (en) * | 2014-09-05 | 2016-03-10 | Allosteros Therapeutics, Inc | CaMKII INHIBITORS AND USES THEREOF |
| UA118610C2 (uk) | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
| SG11201702075QA (en) * | 2014-10-29 | 2017-04-27 | Dong A St Co Ltd | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) |
| CN105288512A (zh) * | 2015-12-08 | 2016-02-03 | 李野林 | 一种治疗肥胖症的中药组合物 |
| ES2993451T3 (en) | 2016-06-13 | 2024-12-30 | Glaxosmithkline Ip Dev Ltd | Substituted pyridines as inhibitors of dnmt1 |
| AU2017312561B2 (en) * | 2016-08-15 | 2022-06-30 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| AU2017312970B2 (en) * | 2016-08-16 | 2021-08-12 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof |
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| JOP20190257A1 (ar) * | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
| KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| KR102563325B1 (ko) | 2017-06-30 | 2023-08-03 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 |
| WO2019001572A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019000683A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| KR102603203B1 (ko) | 2018-07-25 | 2023-11-16 | 파에스 파마, 에스.에이. | 히스타민 h4-수용체 저해제로서 피리도피리미딘류 |
| EP3831823A4 (en) * | 2018-08-01 | 2022-04-27 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION |
| CN111100063B (zh) * | 2018-10-25 | 2022-05-17 | 南京药石科技股份有限公司 | 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法 |
| JP7603605B2 (ja) * | 2019-03-28 | 2024-12-20 | キャンサー・リサーチ・テクノロジー・リミテッド | 非定型プロテインキナーゼｃの阻害剤およびヘッジホッグ経路依存性癌の治療におけるその使用 |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| CN116120243B (zh) * | 2021-11-15 | 2025-07-29 | 都创(上海)医药科技股份有限公司 | aPKC抑制剂化合物中间体片段及其制备方法和应用 |
| CN114349711B (zh) * | 2022-02-28 | 2023-08-15 | 四川依维欣医药科技有限公司 | 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法 |
| CN117088898B (zh) * | 2022-05-13 | 2026-02-06 | 中国药科大学 | 稠环嘧啶类化合物及其制备方法、药物组合物和应用 |
| CN120882714A (zh) * | 2022-12-13 | 2025-10-31 | 风树疗法公司 | {5-环丙基-2-[2-(3,6-二氟-吡啶-2-基氨基)-吡啶-4-基]-吡啶并[3,4-d]嘧啶-4-基}-((s)-3,3-二甲基-哌啶-4-基)-胺的固体形式 |
| CN117343005A (zh) * | 2023-10-08 | 2024-01-05 | 上海泰坦科技股份有限公司 | 一种异烟酸衍生物的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4936700A (enExample) | 1972-08-16 | 1974-04-05 | ||
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| JP2002080423A (ja) * | 2000-09-06 | 2002-03-19 | Daikin Ind Ltd | トリフルオロ酢酸エチルの合成方法 |
| DK1318997T3 (da) * | 2000-09-15 | 2006-09-25 | Vertex Pharma | Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP4895806B2 (ja) * | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| US20050038047A1 (en) * | 2003-08-14 | 2005-02-17 | Edwards Paul John | Azaquinazoline derivatives |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| JP2008531538A (ja) * | 2005-02-25 | 2008-08-14 | クドス ファーマシューティカルズ リミテッド | ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用 |
| AU2007287430B2 (en) * | 2006-08-23 | 2011-07-21 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| RU2009108006A (ru) * | 2006-09-08 | 2010-10-20 | Пфайзер Продактс Инк. (Us) | Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов |
| US8993552B2 (en) * | 2009-09-04 | 2015-03-31 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| MX372736B (es) * | 2012-09-28 | 2020-06-19 | Cancer Research Tech Ltd | Inhibidores de azaquinazolina de la proteina quinasa c atipica. |
| WO2014164543A1 (en) * | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| KR20180103053A (ko) * | 2015-12-22 | 2018-09-18 | 비타이 파마슈티컬즈, 인코포레이티드 | 메닌-mll 상호작용의 억제제 |
-
2013
- 2013-09-27 MX MX2015004016A patent/MX372736B/es active IP Right Grant
- 2013-09-27 KR KR1020157010868A patent/KR102215272B1/ko active Active
- 2013-09-27 SG SG11201502301YA patent/SG11201502301YA/en unknown
- 2013-09-27 BR BR112015007061-2A patent/BR112015007061B1/pt active IP Right Grant
- 2013-09-27 EP EP13774578.2A patent/EP2900666B1/en active Active
- 2013-09-27 WO PCT/US2013/062085 patent/WO2014052699A1/en not_active Ceased
- 2013-09-27 CN CN201380062263.9A patent/CN105102456B/zh active Active
- 2013-09-27 TW TW102134928A patent/TWI663165B/zh active
- 2013-09-27 CA CA2886495A patent/CA2886495C/en active Active
- 2013-09-27 NZ NZ706857A patent/NZ706857A/en unknown
- 2013-09-27 JP JP2015534689A patent/JP6535430B2/ja active Active
- 2013-09-27 US US14/038,915 patent/US9914730B2/en active Active
- 2013-09-27 AU AU2013323360A patent/AU2013323360B2/en active Active
- 2013-09-27 EA EA201590661A patent/EA030253B1/ru not_active IP Right Cessation
-
2015
- 2015-03-24 IL IL237918A patent/IL237918B/en active IP Right Grant
- 2015-03-26 PH PH12015500689A patent/PH12015500689A1/en unknown
- 2015-03-27 CL CL2015000781A patent/CL2015000781A1/es unknown
- 2015-04-23 ZA ZA2015/02783A patent/ZA201502783B/en unknown
- 2015-12-18 US US14/975,605 patent/US9896446B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| MAURICE J VAN EIS ET AL, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, GB, vol. 21, no. 24, doi:10.1016/J.BMCL.2011.10.025, ISSN 0960-894X, (2011-10-07), pages 7367 - 7372, (2011-10-21) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013323360B2 (en) | Azaquinazoline inhibitors of atypical protein kinase C | |
| KR101926245B1 (ko) | Ｔａｎｋ-결합 키나제 억제제 화합물 | |
| ES2902148T3 (es) | Derivados de amidas policíclicas como inhibidores de CDK9 | |
| US10414763B2 (en) | Azaquinazoline inhibitors of atypical protein kinase C | |
| HK1211928B (en) | Azaquinazoline inhibitors of atypical protein kinase c | |
| HK1212336B (en) | Azaquinazoline inhibitors of atypical protein kinase c | |
| HK1236197A1 (en) | Tank-binding kinase inhibitor compounds | |
| HK1236197B (en) | Tank-binding kinase inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED Free format text: FORMER APPLICANT(S): CANCER RESEARCH TECHNOLOGY LIMITED; IGNYTA, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |